Superior vena cava thrombus treated with low-dose, peripherally administered recombinant tissue plasminogen activator in a child: Case report and review of the literature

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 12, 2005, Pages 692-695

  Fasano, Ross ^a   Kent, Paul ^a   Valentino, Leonard ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Septic thromboembolism; Thrombolysis; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LOW DRUG DOSE; MALE; MEDLINE; PRESCHOOL CHILD; PRIORITY JOURNAL; SUPERIOR CAVA VEIN; THROMBUS;

ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTEREMIA; CATHETERIZATION, PERIPHERAL; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; ENOXAPARIN; ESCHERICHIA COLI INFECTIONS; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, LARGE-CELL; MALE; PLATELET TRANSFUSION; RECOMBINANT PROTEINS; SUPERIOR VENA CAVA SYNDROME; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 29144531831     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000194021.40839.05     Document Type: Article

References (12)

1. Monagle P, Michelson AD, Bovill E, et al. Antithrombotic therapy in children. Chest. 2001;119(1 Suppl):3445-3470.
2. Andrew M, Adams M, David M, et al. Venous thromboembolic complications (VTE) in children: first analysis of the Canadian Registry of Venous Thromboembolism. Blood. 1994;83:1251-1257.
3. Chamuleau SA, de Winter RJ, Levy M, et al. Low-molecular-weight heparin as an adjunct to thrombolysis following acute myocardial infarction: the FATIMA study. Fraxiparine Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group. Heart. 1998;80:35-39.
4. Comerota AJ. Thrombolytic therapy for acute deep vein thrombosis. In: Comerota AJ, ed. Thrombolytic Therapy for Acute Vascular Disease. Philadelphia: JB Lippincott, 1995:175-195.
5. Leaker M, Massicotte MP, Brooker L, et al. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost. 1996;76:132-134.
6. Gupta AA, Leaker M, Andrew M, et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr. 2001;139:682-688.
7. Knoffler R, Dinger J, Kabus M, et al. Thrombolytic therapy in children-clinical experiences with recombinant tissue plasminogen activator. Semin Thromb Hemost. 2001;27:169-174.
8. Wang M, Hays T, Balasa V, et al. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol. 2003;25:379-386.
9. Manco-Johnson MJ, Nuss R, Hays T, et al. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr. 2000;136:425-426.
10. Dillon PW, Fox PS, Berg CJ, et al. Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy. J Pediatr Surg. 1993;28:1264-1269.
11. Farnoux C, Camard O, Pinquier D, et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr. 1997;133:137-140.
12. Weiner GM, Castle V, Dipietro MA, et al. Successful treatment of neonatal arterial thrombi with recombinant tissue plasminogen activator. J Pediatr. 1998;133:133-136.